Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > BUSINESS
BUSINESS
- Nycomed Drives Up Takeda’s April-June Sales by 11.5%, but Operating Profits Decline
July 31, 2012
- Nearly 60% of Doctors Feel Generics Might Be Less Effective than Original Drugs: Survey
July 31, 2012
- Research Subsidiary of Eisai to Move to Kobe Strategic Zone
July 31, 2012
- Major Domestic Makers’ Vaccine Business Gains Momentum; Addition of New Vaccines to Public Vaccination Program Could Spark Debate Over Funding
July 31, 2012
- Afatinib Significantly Improves PFS in Japanese NSCLC Patients: BI Japan
July 31, 2012
- Kyowa Kirin Launches Apokyn for Parkinson’s Disease
July 31, 2012
- Sanofi-aventis Reaches Settlement with Sawai, Takata Seiyaku in Allegra Patent Dispute; Allegra’s Use Patent Validity Established
July 31, 2012
- Takeda Resubmits NDAs to US FDA for Alogliptin
July 31, 2012
- DPP-4 Inhibitor “Indispensable” to Strengthen Priority Field: Kyowa Kirin
July 30, 2012
- Kyowa Kirin’s 1st Half Pharmaceuticals Business Log 9.2% Sales Rise, but Operating Profits Fall
July 30, 2012
- US FDA Withholds Approval for Injectafer Due to Manufacturing Facility Issues: Daiichi Sankyo
July 30, 2012
- Approval for Once-Monthly Aripiprazole Hits Snag in US: Otsuka
July 30, 2012
- DSP, Nitto Denko Initiate PII Studies for Transdermal Patch Lonasen
July 30, 2012
- Eisai Receives Approval in Europe for Antiepileptic Perampanel; Launch in September
July 30, 2012
- Market Exclusivity for Lunesta Extended 6 Months in the US: DSP
July 30, 2012
- Celgene Initiates PII Trial in Japan for Revlimid in Treatment-Naïve Patients with Multiple Myeloma
July 30, 2012
- Pfizer Japan Files NDA for Prevnar 13 for Infant Use
July 30, 2012
- Kobayashi Kako Completes Construction of Anticancer Drug Manufacturing Facility
July 30, 2012
- Alfresa Launches Advanced Temperature-controlled Distribution Service
July 30, 2012
- Chugai’s 1st-Half Sales Excluding Tamiflu Down 0.3% in Japan as Mircera Slumps
July 30, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…